This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Withdrawn) An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) sequences provided in SEQ ID NOs:442, 447, 450 and 467;

(b) complements of the sequences provided in SEQ ID NOs:442, 447, 450 and 467;

(c) sequences consisting of at least 10 contiguous residues of a sequence provided in SEQ ID NOs:442, 447, 450 and 467;

(d) sequences that hybridize to a sequence provided in SEQ ID NOs:442, 447, 450 and 467, under highly stringent conditions;

(e) sequences having at least 75% identity to a sequence of SEQ ID NOs:442, 447, 450 and 467;

(f) sequences having at least 90% identity to a sequence of SEQ ID NOs:442, 447, 450 and 467; and

(g) degenerate variants of a sequence provided in SEQ ID NOs:442, 447, 450 and 467.

2. (Canceled)

3. (Withdrawn) An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.

4. (Withdrawn) A host cell transformed or transfected with an expression vector according to claim 3.

5. (Withdrawn) An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2.

6. (Withdrawn) A method for detecting the presence of a cancer in a patient, comprising the steps of:

(a) obtaining a biological sample from the patient;

(b) contacting the biological sample with a binding agent that binds to a polypeptide of claim 2;

(c) detecting in the sample an amount of polypeptide that binds to the binding agent; and

(d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.

7.-8. (canceled)

9. (Withdrawn) An oligonucleotide that hybridizes to a sequence recited in SEQ ID NOs:442, 447, 450 and 467 under highly stringent conditions.

10. (Withdrawn) A method for stimulating and/or expanding T cells specific for a tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:

(a) polypeptides according to claim 2;

(b) polynucleotides according to claim 1; and

(c) antigen-presenting cells that express a polynucleotide according to claim 1,

under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

11. (Withdrawn) An isolated T cell population, comprising T cells prepared according to the method of claim 10.

12.-14. (Canceled)

15. (Withdrawn) A method for determining the presence of a cancer in a patient, comprising the steps of:

(a) obtaining a biological sample from the patient;

(b) contacting the biological sample with an oligonucleotide according to claim 9;

(c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and

(d) compare the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.

16. (Withdrawn) A diagnostic kit comprising at least one oligonucleotide according to claim 9.

17. (Withdrawn) A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group.

18. (Withdrawn) A method for the treatment of lung cancer in a patient, comprising the steps of:

(a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least one component selected from the group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to claim 1; and (iii) antigen presenting cells that express a polypeptide of claim 2, such that T cell proliferate;

(b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient.

19. (Withdrawn) An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a lung tumor protein that comprises a polypeptide having an amino acid

sequence provided in SEQ ID NO:441 or 443, or an amino acid sequence that is encoded by a polynucleotide having the sequence provided in SEQ ID NO:442 or a complement thereof.

20. (Previously Presented) An immunogenic composition comprising an adjuvant, wherein said adjuvant induces a predominantly Th1-type response, and a polypeptide selected from the group consisting of:

(i) a polypeptide comprising the amino acid sequence provided in SEQ ID NO:176, or a portion thereof;

(ii) a polypeptide comprising an amino acid sequence having at least 90% identity to the sequence provided in SEQ ID NO:176, or a portion thereof;

wherein said polypeptide contains an amino acid sequence that is capable of stimulating T cells that are specific for an amino acid sequence present in the polypeptide set forth in SEQ ID NO:176.

21. (Previously Presented) The immunogenic composition according to claim 20, wherein the adjuvant comprises an adjuvant selected from the group consisting of a monophosphoryl lipid A, an aluminum salt, QS21, Montanide ISA 720, SAF, ISCOMS, MF-59, SBAS-2, SBAS-4, Detox, RC-529, and an aminoalkyl glucosaminide 4-phosphate.

22. (Previously Presented) The immunogenic composition according to claim 20, wherein said polypeptide comprises amino acid positions 37-55 of the amino acid sequence provided in SEQ ID NO:176.

23. (Previously Presented) The immunogenic composition according to claim 20, wherein said polypeptide comprises amino acid positions 41-51 of the amino acid sequence provided in SEQ ID NO:176.